The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40-49 and 50-59.
breast cancer
clinical practice
prevention
recommendations
registries
screening mammography
stage shift
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
09 08 2022
09 08 2022
Historique:
received:
23
06
2022
revised:
28
07
2022
accepted:
03
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The relationship between Canadian mammography screening practices for women 40−49 and breast cancer (BC) stage at diagnosis in women 40−49 and 50−59 years was assessed using data from the Canadian Cancer Registry, provincial/territorial screening practices, and screening information from the Canadian Community Health Survey. For the 2010 to 2017 period, women aged 40−49 were diagnosed with lesser relative proportions of stage I BC (35.7 vs. 45.3%; p < 0.001), but greater proportions of stage II (42.6 vs. 36.7%, p < 0.001) and III (17.3 vs. 13.1%, p < 0.001) compared to women 50−59. Stage IV was lower among women 40−49 than 50−59 (4.4% vs. 4.8%, p = 0.005). Jurisdictions with organised screening programs for women 40−49 with annual recall (screeners) were compared with those without (comparators). Women aged 40−49 in comparator jurisdictions had higher proportions of stages II (43.7% vs. 40.7%, p < 0.001), III (18.3% vs. 15.6%, p < 0.001) and IV (4.6% vs. 3.9%, p = 0.001) compared to their peers in screener jurisdictions. Based on screening practices for women aged 40−49, women aged 50−59 had higher proportions of stages II (37.2% vs. 36.0%, p = 0.003) and III (13.6% vs. 12.3%, p < 0.001) in the comparator versus screener groups. The results of this study can be used to reassess the optimum lower age for BC screening in Canada.
Identifiants
pubmed: 36005182
pii: curroncol29080444
doi: 10.3390/curroncol29080444
pmc: PMC9406663
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5627-5643Références
J Natl Cancer Inst Monogr. 1997;(22):87-92
pubmed: 9709282
Cancer. 1997 Dec 1;80(11):2091-9
pubmed: 9392331
JAMA Surg. 2018 Jun 1;153(6):594-595
pubmed: 29516087
Cancer. 2020 Jul 1;126(13):2971-2979
pubmed: 32390151
CMAJ. 1992 Nov 15;147(10):1477-88
pubmed: 1423088
Curr Oncol. 2014 Dec;21(6):281-93
pubmed: 25489255
Eur J Public Health. 2012 Jun;22(3):413-8
pubmed: 21746751
Breast Cancer Res Treat. 1997 Sep;45(3):263-70
pubmed: 9386870
Health Rep. 1996 Autumn;8(2):29-37(Eng); 31-40(Fre)
pubmed: 9110963
Br J Cancer. 2004 Mar 22;90(6):1138-43
pubmed: 15026792
J Clin Oncol. 2016 Sep 20;34(27):3308-14
pubmed: 27480155
Health Rep. 2021 Sep 15;32(9):14-26
pubmed: 34523870
Breast Cancer Res Treat. 2021 May;187(1):295-297
pubmed: 33770312
Eur J Cancer. 2022 Jul 12;173:1-9
pubmed: 35839596
J Am Coll Radiol. 2013 May;10(5):317-9; discussion 323
pubmed: 23542028
J Med Screen. 2022 Mar;29(1):7-11
pubmed: 34812692
Can Fam Physician. 2020 May;66(5):321-326
pubmed: 32404449
Curr Oncol. 2022 May 30;29(6):3894-3910
pubmed: 35735420
Cancer. 2019 Feb 15;125(4):515-523
pubmed: 30411328
JAMA. 1971 Mar 15;215(11):1777-85
pubmed: 5107709
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
Curr Oncol. 2016 Dec;23(6):e615-e625
pubmed: 28050152
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
Ann Oncol. 2011 Aug;22(8):1726-35
pubmed: 21252058
Ann Oncol. 2021 Aug;32(8):1015-1024
pubmed: 34102253
Can Assoc Radiol J. 2022 Feb;73(1):90-100
pubmed: 34279132
J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203
pubmed: 16106024
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274578
CMAJ Open. 2018 Feb 8;6(1):E77-E86
pubmed: 29440151
BMJ. 1988 Oct 15;297(6654):943-8
pubmed: 3142562
Ann Intern Med. 2021 Dec;174(12):1637-1646
pubmed: 34662151
Lancet. 1990 Feb 3;335(8684):241-6
pubmed: 1967717
AJR Am J Roentgenol. 2018 Feb;210(2):264-270
pubmed: 29064760
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
J Am Coll Radiol. 2020 Oct;17(10):1269-1275
pubmed: 32473894
Lancet. 1985 Apr 13;1(8433):829-32
pubmed: 2858707
Eur J Public Health. 2022 Aug 1;32(4):630-635
pubmed: 35732293
J Med Screen. 2012;19 Suppl 1:42-56
pubmed: 22972810
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):225-34
pubmed: 14973097
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
BMJ. 2014 Feb 11;348:g366
pubmed: 24519768
CMAJ. 1992 Nov 15;147(10):1459-76
pubmed: 1423087
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1699-705
pubmed: 19505902
CMAJ. 2011 Nov 22;183(17):1991-2001
pubmed: 22106103
Breast Cancer Res Treat. 2021 Jan;185(2):507-515
pubmed: 33064230
Cancers (Basel). 2019 Apr 08;11(4):
pubmed: 30965658
Cancer. 1995 Apr 1;75(7):1619-26
pubmed: 8826919
J Med Screen. 2015 Dec;22(4):194-200
pubmed: 26081449
CMAJ. 2018 Dec 10;190(49):E1441-E1451
pubmed: 30530611
Cancer. 1994 Jul 1;74(1 Suppl):222-7
pubmed: 8004590
J Prim Care Community Health. 2022 Jan-Dec;13:21501327211058322
pubmed: 35068237
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919
J Natl Cancer Inst. 2014 Sep 12;106(10):
pubmed: 25217577